Company / Cash & Equivalents
Nurix Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$247.0M
FY2025
5-year range
$54.6M / $247.0M
FY2021-FY2025
Trend
+124.5%
vs FY2024
Sector context
#70 of 207
Health Care
What the data says
At $247M, Nurix Therapeutics, Inc.'s cash & equivalents ranks #70 of 207 in the Health Care sector. Improved from $55M to $247M over the past 2 years.
Based on SEC 10-K filings.
$247M in FY2025 with a 5-year CAGR of +15.7%.
Improved from $55M to $247M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +56.5%
- 5-Year CAGR
- +15.7%
- 10-Year CAGR
- -
Sector benchmark
#70 of 207 in Health CareTop 34% of 207This company $247.0M Sector average $669.5M
▼
-63.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 124.5% year-over-year.
- Ranks #70 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $247.0M | +124.5% |
| FY2024 | $110.0M | +101.4% |
| FY2023 | $54.6M | -15.3% |
| FY2022 | $64.5M | -19.9% |
| FY2021 | $80.5M | -32.5% |
| FY2020 | $119.4M | +242.8% |
| FY2019 | $34.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026